Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2015—The Digital Pathology Association is commending the FDA for developing and releasing draft guidance that provides industry and agency staff with recommendations regarding the technical performance assessment data that should be submitted for regulatory evaluation of a digital whole-slide imaging system.
April 2015—Qiagen has expanded its portfolio of liquid biopsies through the acquisition of a proprietary technology from AdnaGen. The technology allows a complete solution for the detection and analysis of circulating tumor cells for clinical applications. It enriches disease-specific tumor cells using magnetic particles in an antibody mixture, then isolates and purifies messenger RNA for analysis using reverse transcription polymerase chain reaction.
April 2015—Agena Bioscience released the MassArray 24-Well System for mass spectrometry-based genetic analysis. The 24-well format is tailored to smaller clinical testing laboratories requiring modest sample throughput, reduced initial hardware costs, and reduced time to result.
April 2015—Eppendorf and the journal Science are accepting applications for the 2015 Eppendorf & Science Prize for Neurobiology.
April 2015—The diagnostics division of Siemens Healthcare has announced the U.S. availability of its Advia Centaur Syphilis assay to be used as a diagnostic aid. The assay, which allows for sensitive and specific detection of antibodies to the proteins of Treponema pallidum in human serum or plasma (EDTA, lithium or sodium heparinized, sodium citrate), is available on the company’s Advia Centaur, Centaur XP, and Centaur CP immunoassay systems. It is not intended for blood and tissue donor screening.
April 2015—Agendia received 510(k) clearance from the Food and Drug Administration for its MammaPrint breast cancer recurrence test in formalin-fixed, paraffin-embedded tissue.
April 2015—Rosetta Genomics has entered into a co-promotional commercial partnership with Precipio Diagnostics for the sales and marketing of Precipio’s oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas. These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia, and Washington, DC, with an expectation to expand nationally over time.
April 2015—Applied Spectral Imaging has received FDA clearance for its GenASIs HiPath image capture and analysis platform. The ASI platform for immunohistochemistry samples integrates with existing lab microscopes and workflows, aiming to provide labs with a cost-effective solution for digital pathology.
April 2015—Thermo Fisher Scientific has released a next-generation sequencing RNA panel and workflow that enables targeted sequencing of fusion transcripts for clinical research. The Ion Torrent AmpliSeq RNA Fusion Lung Cancer Research Panel allows simultaneous sequencing of 70 ALK, RET, ROS1, and NTRK1 fusion transcripts associated with lung cancer as well as 5’ and 3’ ALK gene expression.
April 2015—Definiens announced the newest version of its image analysis software for quantitative digital pathology, Tissue Studio 4.0. By providing morphological fingerprints and biomarker expression profiles on a cell-by-cell basis, the software enables comprehensive and consistent data for any tissue-based assay. It is also able to handle biological variation and staining heterogeneity.
